GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BNT-211 overview
BNT-211 is under development for the treatment of multiple solid tumors include endometrial cancer, sarcoma, testicular cancer, ovarian cancer, fallopian tube cancer, peritoneal tumor, non-small cell lung cancer, gastric cancer and uterine cancer The drug candidate is an adaptive T cell immunotherapeutic to treat cancers by engineering chimeric antigen receptors (CARs). The therapeutic candidate is developed using the using the Unicell technology enabling high-throughput cloning and validation of human T cell receptors (TCRs) from single antigen reactive T lymphocytes. The therapy targets cells expressing claudin 6.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
BioNTech overview
BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell and gene therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, malaria, hepatitis B, influenza, and COVID-19. BioNTech uses FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Pfizer, Genmab AS and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
For a complete picture of BNT-211’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#BNT211 #BioNTech #Testicular #Cancer #Likelihood #Approval
